US vaccines group calls for Congressional hearings on federal agencies' failure to provide adequate safety research

25 February 2010

In a letter to the Chairmen and Ranking Members of the USA's House and Senate Committees charged with oversight of the Department of Health and Human Services (HHS), the Coalition for Vaccine Safety (CVS) is calling for hearings to investigate HHS, the Centers for Disease Control (CDC) and other government agencies for failure to fully address issues of vaccine safety as intended by the Mandate for Safer Vaccines in the 1986 National Childhood Vaccine Injury Compensation Act.

With the federal government claiming "case closed" on possible damage to children caused by compulsory vaccines, too much evidence exists and too many unanswered questions remain, according to the letter. Key concerns are: insufficient and flawed data knowingly and willing used by government entities to reach conclusions that science dictates simply cannot be reached; conflicts of interest of individuals and government agencies involved in vaccine safety research; and ignored statements from experts regarding the un-answered question of a link between thimerosal (mercury) in vaccines and autism.

Quoting various sources in support of its argument, the CVS included the following:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical